• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

No benefit of myo-inositol on type 1 retinopathy of prematurity in preterm Infants

byQasim HussainiandDaniel Fisher
October 23, 2018
in Chronic Disease, Ophthalmology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, both mortality and retinopathy of prematurity (ROP) type 1 occurred more often in preterm infants treated with myo-inositol than in those treated with placebo.

2. Necrotizing enterocolitis and hypotension were noticable adverse effects in the Myo-inositol group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A common morbidity in preterm infants is ROP. Previous studies conducted up to 2 decades ago and a more recent Cochrane meta-analysis have shown the benefits of myo-inositol in reducing pre-term death and ROP. In this randomized controlled trial, the safety and efficacy of this treatment in infants younger than 28 weeks’ gestation in reducing rates of type 1 ROP was tested against placebo. Infants treated with myo-inositol had higher rates of mortality and type 1 than infants treated with placebo. Common adverse effects of myo-inositol were necrotizing enterocolitis, poor perfusion, hypotension, and intraventricular hemorrhage.

Overall, this study suggests the opposite result of other analyses, namely that myo-inositol may increase the rate of death and type 1 ROP in preterm infants. Limitations of this study include inadequate sample size to make definitive conclusions regarding efficacy and not being formally powered to make conclusions regarding safety of myo-inositol. Early termination of the trial also limited definitive conclusions.

Click to read the study, published today in JAMA

Relevant Reading: Inositol for respiratory distress syndrome in preterm infants

RELATED REPORTS

Extreme prematurity associated with increased prevalence of visual and ocular deficits in young adults

Increased survival without major morbidity noted among very low birthweight infants in California

Digital imaging detects sight-threatening retinopathy of prematurity

In-Depth [randomized controlled trial]: The study was a double-blind placebo-controlled randomized clinical trial. Inclusion criteria included infants born before 28 0/7 weeks of gestation, surviving for at least 12 hours, and admitted to one of the participating centers before 72 hours’ postnatal age. Exclusion criteria included any major congenital anomaly, eye anomaly, or moribund condition. Randomization was done using computer-generated methods. The treatment dose was 40 mg/kg every 12 hours of myo-inositol (or placebo which was 5% glucose) for 10 weeks. The primary unfavorable outcome was type 1 ROP or death before the ROP outcome could be realized. The favorable primary outcome was survival with only milder ROP or no ROP. Infants were followed up to maximum of 55 weeks’ post-menstrual age. Secondary outcomes included occurrence of any type of ROP, self-resolving type 2 ROP or greater, and all-cause mortality up to 55 weeks’ post-menstrual age. Overall, death and type 1 ROP occurred more frequently in the myo-inositol group (29% vs 21%, adjusted relative risk, 1.41; CI95 1.08-1.83). All-cause death before 55 weeks’ post-menstrual age also occurred more frequently in the myo-inositol group (18% vs 11%, adjusted relative risk, 1.66; CI95 1.14-2.43).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: retinopathy of prematurity (ROP)
Previous Post

Replacement of recipient hematopoietic cells with donor cells may be a major factor in HIV remission after allo-HSCT

Next Post

2 Minute Medicine Rewind October 23, 2018

RelatedReports

Low evidence for glycerin use in preterm infants
Chronic Disease

Extreme prematurity associated with increased prevalence of visual and ocular deficits in young adults

January 31, 2022
Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial
Pediatrics

Increased survival without major morbidity noted among very low birthweight infants in California

June 18, 2020
Digital imaging detects sight-threatening retinopathy of prematurity
Ophthalmology

Digital imaging detects sight-threatening retinopathy of prematurity

December 15, 2015
Next Post
Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure

2 Minute Medicine Rewind October 23, 2018

Gene therapy targets Duchenne muscular dystrophy in new trial [PreClinical]

Gene therapy targets Duchenne muscular dystrophy in new trial [PreClinical]

Pre-operative transcranial magnetic stimulation useful for language mapping

Adolescents, girls more vulnerable to persistent postconcussion symptoms

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.